ADX-097 is under clinical development by Q32 Bio and currently in Phase I for Inflammation. According to GlobalData, Phase I drugs for Inflammation have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ADX-097’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ADX-097 is under development for the treatment of severe inflammatory and autoimmune diseases. The drug candidate is a humanized anti-C3d monoclonal antibody linked to two moieties of the first five consensus repeats of the complement negative regulatory protein human factor H (fH1-5), designed to target complement inhibition.
Q32 Bio overview
Q32 Bio, formerly Admirx, is a bio pharmaceutical manufacturing company based in the US. The company is engaged in the manufacture of therapeutic drugs for restoring immune homeostasis. The innate immunity includes the complement system, which can be activated in three ways by cleaving component proteins like Complement Component 3 (C3) into smaller protein fragments. These protein fragments perform a variety of functions, including cell debris clearance, pathogenic intruder elimination, and adaptive immunity modulation. Q32 Bio is headquartered in Waltham, Massachusetts, the US.
For a complete picture of ADX-097’s drug-specific PTSR and LoA scores, buy the report here.